infection in an endemic setting in the Netherlands
M. P. M. Hensgens, A. Goorhuis, C. M. J. Kinschot, M. J. T. Crobach, C. Harmanus, E. J. Kuijper

To cite this version:
M. P. M. Hensgens, A. Goorhuis, C. M. J. Kinschot, M. J. T. Crobach, C. Harmanus, et al.. infection in an endemic setting in the Netherlands. European Journal of Clinical Microbiology and Infectious Diseases, Springer Verlag, 2010, 30 (4), pp.587-593. 10.1007/s10096-010-1127-4. hal-00655578

HAL Id: hal-00655578
https://hal.archives-ouvertes.fr/hal-00655578
Submitted on 31 Dec 2011
Clostridium difficile infection in an endemic setting in the Netherlands

Marjolein P.M. Hensgens\textsuperscript{1} / Abraham Goorhuis\textsuperscript{1}, Caroline M.J. van Kinschot\textsuperscript{1},
Monique J.T. Crobach\textsuperscript{1}, Celine Harmanus\textsuperscript{1}, Ed J. Kuijper\textsuperscript{1}

\textsuperscript{1} Leiden University Medical Center, Department of Medical Microbiology, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden

* both authors contributed equally

Corresponding author:
E.J. Kuijper, Department of Medical Microbiology, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden. The Netherlands.
Email: E.J.Kuijper@lumc.nl Tel: +31 71 526 3574 Fax: +31 71 524 8148

Category: original article

Key words: Clostridium difficile infection, risk factor, endemic, fluoroquinolones, mortality

40-word summary: Risk factors for Clostridium difficile infections (CDI) in an endemic setting differ from those in outbreak situations. Some risk factors that have earlier been ascribed to CDI were in this study not specific for CDI, but for diarrhoea in general.

Running title: Risk factors for endemic CDI


Abstract

Purpose: To study risk factors for *Clostridium difficile* infection (CDI) in an endemic setting.

Methods: In a 34 month prospective case-control study, we compared risk factors and clinical characteristics of all consecutively diagnosed hospitalized CDI patients (n=93) with those of patients without diarrhoea (n=76) and patients with non-CDI diarrhoea (n=64).

Results: The incidence of CDI was 17.5 per 10,000 hospital admissions. *C. difficile* PCR-ribotype 014 was the most frequently found type (15.9%), followed by types 078 (12.7%) and 015 (7.9%). Independent risk factors for endemic CDI were use of second generation cephalosporins, previous hospital admission and previous stay at the intensive care unit. Use of third generation cephalosporins was a risk factor for diarrhoea in general. We found no association of CDI with the use of fluoroquinolones or proton pump inhibitors. The overall 30-day mortality rates among CDI patients, patients without diarrhoea and patients with non-CDI diarrhoea were 7.5%, 0% and 1.6% respectively.

Conclusions: In this endemic setting, risk factors for CDI differed from those in outbreak situations. Some risk factors that have earlier been ascribed to CDI were in this study not specific for CDI, but for diarrhoea in general. Thirty-day mortality among CDI patients was relatively high.
Introduction

Since 2002, outbreaks caused by Clostridium difficile infection (CDI) have been reported in Canada, the USA and Europe, associated with the emergence of a new hypervirulent type. This type has been characterized as North American pulsed-field type 1, restriction-endonuclease analysis group type BI, toxinotype III and PCR-ribotype 027 (type 027) [1-5]. During outbreaks in the USA and Canada, the reported incidences of CDI varied between 155 and 225 per 10,000 hospital admissions [3, 6]. Peak incidences of CDI due to type 027 during outbreaks in the Netherlands were remarkably lower, around 50 per 10,000 hospital admissions [7, 8].

Most recent studies on risk factors of CDI focussed on outbreaks, whereas less is known about CDI in settings with a low incidence. Well described risk factors for CDI in outbreak situations are prior use of antibiotics, increased disease severity, and, in case of outbreaks caused by type 027, advanced age and prior use of fluoroquinolones [9-11].

The aim of our study was to identify risk factors for CDI in a true endemic setting. A second aim was to establish risk factors specific for CDI, in comparison with factors for diarrhoea in general. To answer these questions, we performed a prospective case-control study at the Leiden University Medical Center during a period of 34 months.
Methods

Patients.

From July 2006 through April 2009, all hospitalized patients with CDI were included in the study. Tests for CDI were performed daily upon request and on all unformed faecal samples from patients admitted for two days or more, regardless the physicians’ request. For each hospitalized CDI patient, two controls were included, matched for ward at which CDI was diagnosed and time of admission. The controls included one control patient without diarrhoea (control patient) and one control patient with diarrhoea and a negative C. difficile toxin test (non-CDI patient). Controls were consecutive patients on the alphabetical ward list.

Definitions.

Definitions as proposed by the European and American Centres of Disease Control were used [2, 12]. Diarrhoea was defined as ≥3 unformed stools per 24 hours. CDI was defined as the presence of diarrhoea in combination with a positive toxin test for C. difficile. A community association was defined as development of CDI outside the hospital or within 48 hours after admission, without a history of admission in the previous three months. We defined diarrhoea as severe, when it occurred with one or more of the following: bloody stools, hypovolemia, fever (T>38.0°C) and leucocytosis (>12.0x10⁹/l), hypo-albuminemia (<20 g/l), pseudomembranous colitis. A complicated course of CDI was defined as: admission to the intensive care unit (ICU), a surgical intervention in
association with CDI, or death within one month. Mortality was considered contributable to CDI when a patient died during admission, partly due to the consequences of CDI.

**Isolation and characterization of *Clostridium difficile***.

*C. difficile* toxins in stools were detected by VIDAS *C. Diff.* toxin A during the first 12 months of the study and VIDAS toxin A/B assay during the ensuing 22 months (BioMérieux, France). Each positive sample was cultured. Available isolates were identified as *C. difficile* using a PCR to detect the presence of *gldD* and were PCR-ribotyped as previously described [8, 13].

**Data collection.**

Approval was obtained from the Medical Review Ethics Committee to collect demographical and clinical patient data. Information was collected on patients' age, sex, co-morbidity, ward of acquisition, disease severity, clinical course and mortality. Furthermore, data were collected on surgery, invasive procedures, admissions, use of antibiotics and other medications in the 3 months prior to CDI. We gathered this information through consultation of the physician in charge, as well as by using patient records and the hospital electronic medical information system. The period of 3 months prior to CDI was determined by calculating backwards from a reference date. For CDI and non-CDI patients, this reference date was defined as the day on which the diarrhoea started. The reference date for control patients was determined by adding the hospitalized period of the matched CDI patient (time between admission and start of diarrhoea) to the admission date of the control patient. Co-morbidity was assessed by
both the Charlson co-morbidity index and the ICD-10 classification in ten disease
groups; mentioned in table 1 [14].

**Statistical analysis.**

Continuous data were compared between groups using the T-test. The
Pearson’s-chi-square test and the Fisher’s exact test were used for the analysis of
proportions. Factors that were associated in univariate analysis (UVA) with a p-value
<0.10, as well as putative risk factors from earlier studies, were analyzed in a
multivariable model. Here, associations were always adjusted for age, sex, ward and
Charlson co-morbidity index. To evaluate the effect of medications and interventions on
(CDI) diarrhoea, we performed additional adjustments for co-medication and other
interventions. When comparing non-CDI patients with control patients, we also corrected
for the time between admission and the reference date. Relative risks were estimated as
odds ratios (OR) and presented with a 95% confidence interval (95% CI). Statistical
significance was reached with a 2-sided p-value <0.05; trends were defined by a p-value
<0.10. All analyses were performed using the SPSS for Windows software package,
version 17.0.
Results

During the 34 month study period, 93 patients were diagnosed with CDI. The incidence varied from 0 to 43 per 10,000 hospital admissions with an average of 17.5. During this period, no outbreaks were observed. CDI was community associated in four patients (4.3%). Most patients (n=30; 32.3%) were hospitalized at the department of internal medicine, followed by the general surgery ward (n=15; 16.1%). Eighty-nine CDI patients were positive on both toxin testing and culture (95.7%). Isolates from 63 (67.7%) patients were available for PCR-ribotyping: type 014 was the most frequently found type (n=10; 15.9%), followed by types 078 (n=8; 12.7%) and 015 (n=5; 7.9%). Type 027 was not present. Three patients with CDI had a co-infection with an enterovirus, norovirus, and Cryptosporidium, respectively.

The 93 CDI patients were compared to 76 control patients and 64 patients with non-CDI diarrhoea. Of all patients, physicians responded and records were available, however, in some cases (the exact number is depicted in the subscript of table 1) no information about use of nasogastric intubation, surgery or endoscopy was noted.

In the group of non-CDI patients, two patients were diagnosed with a rotavirus and Giardia Lamblia, respectively. Among the other 62 patients no causal agent was found. CDI patients had a median age of 56 years; non-CDI diarrhoea and control patients had a median age of 50 years. Of the CDI patients, 60% were male, compared to 50% and 54% of the non-CDI and control patients, respectively. The time span
between admission and start of diarrhoea did not significantly differ between CDI and non-CDI patients.

**Characteristics and risk factors.**

We present baseline characteristics and risk factors for CDI and non-CDI diarrhoea in tables 1 and 2. The use of antibiotics as a risk factor for CDI and non-CDI is depicted in table 3. All following results reached statistical significance in multivariable analysis (MVA), unless otherwise stated.

**Age.** Patients with CDI were older than control patients (age > 65 years in 35.5% vs. 23.7%; trend in MVA).

**Comorbidity.** Both CDI and non-CDI diarrhoeal patients had a higher Charlson co-morbidity index (index of 3-4 or >5) than control patients (not significant). CDI patients were more likely to have haematological malignancies, diseases of the urogenital tract or other diseases (all trends in MVA). The category ‘other diseases’ comprised organ transplants in 69.7%.

**Use of medications.** Compared to control patients, patients with CDI more frequently used antibiotics, specifically second and third generation cephalosporins. CDI patients also more frequently used penicillin and vancomycin (all significant only in UVA). Furthermore, CDI patients used proton pump inhibitors (PPIs) more frequently (significant only in UVA). The use of antacids (17.2% vs. 18.4%; OR 0.68; 95% CI 0.26-1.79) or the combined use of PPIs and antacids (74.2% vs. 59.2%; OR 0.75; 95% CI
was not significantly more frequent in patients with CDI in MVA (data not shown in the table).

Compared to control patients, patients with non-CDI diarrhoea more frequently used third generation cephalosporins but less frequently used first generation cephalosporins.

**Interventions and admissions.** Patients with CDI, compared to control patients, were more frequently admitted in the previous 3 months, either at the hospital or ICU department. They also more frequently had a nasogastric intubation or an endoscopy (significant only in UVA).

Patients with non-CDI diarrhoea more frequently had a nasogastric intubation (significant only in UVA), and were more frequently admitted to the ICU in the previous 3 months (trend in MVA).

**Clinical course.**

Severe diarrhoea was present among 51 hospitalized patients with CDI (58.6%) and 25 patients with non-CDI diarrhoea (39.7%) (OR 2.22; 95% CI 1.14-4.30). No significant differences between CDI and non-CDI diarrhoeal patients were found regarding the frequency of fever (55.6% resp. 43.3%), bloody stools (12.2% resp. 12.9%) or abdominal pain (54.5% resp. 48.2%). CDI patients did however have a higher white blood cell count (≥15 x 10^9/l: 49.9% resp. 30.0%, OR 2.28; 95% CI 1.13-4.59).

Most patients with CDI were treated with metronidazole (n=57; 63.3%), two patients (2.2%) were treated with vancomycin and in 27 patients (30.0%) no specific CDI
treatment was initiated. The 30-day and 60-day mortality rates are depicted in figure 1.

At one month follow-up, a complicated course was observed in 9 CDI patients (10.3%), comprising two colectomies, four ICU admissions due to CDI and seven deaths (7.5%). CDI contributed directly to three of these deaths, but was not the primary cause. One non-CDI patient (1.6%) and none of the control patients died at one month follow-up. No significant association were detected between the severity of the diarrhoea, treatment or outcome.
Discussion

In this 34 months prospective case control study, risk factors for CDI were studied in an endemic setting with a low incidence rate of CDI. The inclusion of a control group of patients with diarrhoea, tested negative for CDI, enabled us to discriminate between risk factors for CDI and for diarrhoea in general.

Common risk factors for CDI outbreaks, such as age above 65 years and a high comorbidity index, were recognized as trends in our study. This may be due to the fact that these risk factors are of less importance in endemic settings, resulting in a lack of power to discern these risk factors. Other well known risk factors for CDI, such as the use of second generation cephalosporins and previous (ICU) admission were also found in this endemic situation [3, 10, 15]. Conversely, the use of fluoroquinolones or PPIs was not a risk factor for CDI. Furthermore, the previous use of third generation cephalosporins was a risk factor for diarrhoea in general.

The CDI incidence in our hospital was lower than that described in other studies in endemic situations, but comparable to the incidence of 18 per 10,000 hospital admissions found in other Dutch hospitals [16]. Recently, a retrospective study analyzing risk factors for CDI in an endemic setting in USA reported an incidence rate of CDI of 106 per 10,000 hospital admissions, which is a factor 5 higher than what we found in this study [10]. There seems to be a considerable difference, per hospital and per country, in the application of the definition of endemic CDI. Therefore, reported rates of endemic CDI may merely reflect a baseline incidence.
In outbreak situations, the previous use of fluoroquinolones has been recognized as an important risk factor for CDI [9, 11, 17, 18]. This association may be due to disruption of the gut flora by newer fluoroquinolones or the high fluoroquinolone resistance found among hypervirulent type 027 strains [19]. Although fluoroquinolones (mainly ciprofloxacin) were frequently prescribed in this study, we found no association with CDI. An explanation could be that we did not encounter type 027 in our hospital. The most frequently found PCR-ribotypes in our study (types 014, 078 and 015) are commonly found in the Netherlands and Europe and are more susceptible to fluoroquinolones than type 027 [11].

The use of vancomycin was previously recognized as a risk factor for endemic CDI [10]. Instead, in this study, the association between vancomycin and CDI was strongly confounded by concomitant use of second and especially third generation cephalosporins (the combination is part of the in-house empirical sepsis therapy) and was not a risk factor for CDI.

PPIs raise the gastric pH, which is associated with enhanced bacterial colonization of first part of the GI-tract. Studies to the use of PPIs in association with CDI revealed conflicting conclusions [20, 21]. In our study, we found no association of the use of PPIs with CDI. It should be noted that half of the non-CDI and control patients also used PPIs.

Earlier studies have found high contamination and colonization rates with *C. difficile* spores in the hospital environment, among hospitalized patients and
asymptomatic carriers [22, 23]. A high colonization pressure on a ward (exposure in time to multiple colonized or infected patients) is associated with an increased risk of CDI [10]. To insure that CDI and control patients were exposed to a similar colonization pressure, we selected control patients from the same ward as CDI patients using the same time period between admission and reference date [24].

We observed contributable and overall mortality rates of 3.2% and 7.5% after 30-days follow-up, respectively. These rates are in between the overall 30-day mortality rate of 4.7%, found in an endemic setting in Canada, and a reported rate of 20% after 60 days in a U.S. study [25, 26]. These mortality rates are much lower than those reported during outbreaks caused by the type 027 strain [3, 11, 26, 27]. In the Netherlands, a complicated course due to type 027 was described in 12.5%, with an attributable mortality rate of 6.3% [9].

Our study has several limitations. First, we used the presence of toxins in faeces as a screening test for CDI which is in agreement with the European recommendations [28]. An alternative standard for diagnosing CDI is the detection of C. difficile in faeces by toxinogenic culture or PCR. Application of this definition could have resulted in a different case and non-CDI control group. However, none of the patients with non-CDI diarrhoea developed CDI at a later moment during admission, which was in accordance with the high negative predictive value of our toxin test. Second, although the endemic incidence found in our study is comparable to that in other Dutch hospitals, it is lower
than incidence rates reported in other studies in endemic situations, which can imply that
our findings may not be applicable to endemic situations in other countries [8, 26, 29].

In conclusion, in this endemic setting, some risk factors for CDI were similar to
those found in outbreak situations, but some risk factors that have earlier been ascribed
to CDI were in this study not specific for CDI, but for diarrhoea in general. Use of
fluoroquinolones and PPIs did not influence the risk of endemic CDI. CDI patients were
more severely ill than non-CDI diarrhoeal patients, as illustrated by a higher leukocyte
count and the relatively high 30- and 60-day mortality. Because CDI is the most
important cause of nosocomial diarrhoea, more studies are needed to determine the
long term outcome associated with C. difficile infections.
Transparency declarations

This study was funded by a grant from ZonMw (grant number 4726)
(1) Joseph R, Demeyer D, Vanrenterghem D, van den BR, Kuijper E, Delmee M. First isolation of Clostridium difficile PCR ribotype 027, toxinotype III in Belgium. Euro Surveill 2005 Oct; 10(10):E051020.

(2) Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006 Oct; 12 Suppl 6:2-18.

(3) Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005 Dec 8; 353(23):2442-9.

(4) McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005 Dec 8; 353(23):2433-41.

(5) Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005 Mar; 26(3):273-80.

(6) Kazakova SV, Ware K, Baughman B, et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 2006 Dec 11; 166(22):2518-24.

(7) Kuijper EJ, van den Berg RJ, Debast S, et al. Clostridium difficile ribotype 027, toxinotype III, the Netherlands. Emerg Infect Dis 2006 May; 12(5):827-30.

(8) Paltansing S, van den Berg RJ, Guseinova RA, Visser CE, van d, V, Kuijper EJ. Characteristics and incidence of Clostridium difficile-associated disease in The Netherlands, 2005. Clin Microbiol Infect 2007 Nov; 13(11):1058-64.

(9) Goorhuis A, van der KT, Vaessen N, et al. Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis 2007 Sep 15; 45(6):695-703.

(10) Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007 Dec 15; 45(12):1543-9.
(11) Hubert B, Loo VG, Bourgault AM, et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. Clin Infect Dis 2007 Jan 15; 44(2):238-44.

(12) McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007 Feb; 28(2):140-5.

(13) Bidet P, Lalande V, Salauze B, et al. Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile. J Clin Microbiol 2000 Jul; 38(7):2484-7.

(14) Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5):373-83.

(15) Nelson DE, Auerbach SB, Baltch AL, et al. Epidemic Clostridium difficile-associated diarrhea: role of second- and third-generation cephalosporins. Infect Control Hosp Epidemiol 1994 Feb; 15(2):88-94.

(16) Hensgens MP, Goorhuis A, Notermans DW, van Benthem BH, Kuijper EJ. Decrease of hypervirulent Clostridium difficile PCR ribotype 027 in the Netherlands. Euro Surveill 2009; 14(45).

(17) Bourgault AM, Lamothe F, Loo VG, Poirier L. In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Quebec, Canada. Antimicrob Agents Chemother 2006 Oct; 50(10):3473-5.

(18) Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005 Nov 1; 41(9):1254-60.

(19) Weiss K. Clostridium difficile and fluoroquinolones: is there a link? Int J Antimicrob Agents 2009 Mar; 33 Suppl 1:S29-S32.

(20) Dial S, Delaney JA, Barkun AN, Sussia S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005 Dec 21; 294(23):2989-95.
Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis 2006 Nov 15; 43(10):1272-6.

Dubberke ER, Reske KA, Noble-Wang J, et al. Prevalence of Clostridium difficile environmental contamination and strain variability in multiple health care facilities. Am J Infect Control 2007 Jun; 35(5):315-8.

McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989 Jan 26; 320(4):204-10.

Goorhuis A, van Dissel JT, Kuijper EJ. Novel risk factors for Clostridium difficile-associated disease in a setting of endemicity? Clin Infect Dis 2008 Aug 1; 47(3):429-30.

Dubberke ER, Butler AM, Reske KA, et al. Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. Emerg Infect Dis 2008 Jul; 14(7):1031-8.

Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004 Aug 31; 171(5):466-72.

Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005 Oct 25; 173(9):1037-42.

Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 2009 Dec; 15(12):1053-66.

Alfa MJ, Du T, Beda G. Survey of incidence of Clostridium difficile infection in Canadian hospitals and diagnostic approaches. J Clin Microbiol 1998 Jul; 36(7):2076-80.
### Table 1: Baseline characteristics of patients with CDI, patients with non-CDI diarrhea and control patients.

| Risk factors                        | CDI patients (N=93) | Non-CDI patients (N=64) | Control patients (N=76) |
|-------------------------------------|---------------------|-------------------------|-------------------------|
|                                     | N (%)               | N (%)                   | N (%)                   |
| Age > 65 years                      | 33 (35.5)           | 18 (28.1)               | 18 (23.7)               |
| Male sex                            | 56 (60.2)           | 32 (50.0)               | 41 (53.9)               |
| Charlson co-morbidity index         |                     |                         |                         |
| 0                                   | 14 (15.1)           | 12 (18.8)               | 19 (25.0)               |
| 1-2                                 | 38 (40.9)           | 26 (40.6)               | 32 (42.1)               |
| 3-4                                 | 28 (30.1)           | 15 (23.4)               | 18 (23.7)               |
| 5+                                  | 13 (14.0)           | 11 (17.2)               | 7 (9.2)                 |
| Any underlying disease              | 90 (96.8)           | 61 (95.3)               | 70 (92.1)               |
| Malignancy                          | 24 (26.1)           | 18 (28.1)               | 21 (27.6)               |
| Solid tumor                         | 10 (10.9)           | 5 (7.8)                 | 11 (14.5)               |
| Hematologic malignancy              | 15 (16.1)           | 13 (20.3)               | 10 (13.2)               |
| Endocrine diseases                  | 26 (28.0)           | 16 (25.0)               | 20 (26.3)               |
| Respiratory tract diseases          | 14 (15.1)           | 9 (14.1)                | 8 (10.5)                |
| Gastro-intestinal tract diseases    | 36 (38.7)           | 16 (25.0)               | 21 (27.6)               |
| Cardiovascular tract diseases       | 42 (45.2)           | 27 (42.2)               | 30 (39.5)               |
| Urogenital tract diseases           | 42 (45.2)           | 21 (32.8)               | 24 (31.6)               |
| Nervous system diseases             | 6 (6.5)             | 4 (6.2)                 | 6 (7.9)                 |
| Infectious diseases                 | 13 (14.3)           | 6 (9.4)                 | 7 (9.2)                 |
| Muscular / conn. tissue diseases    | 10 (10.8)           | 4 (6.2)                 | 7 (9.2)                 |
| Other diseases                      | 36 (39.1)           | 24 (37.5)               | 22 (28.9)               |
| Any antibiotic                      | 87 (93.5)           | 48 (75.0)               | 51 (68.0)               |
| Proton pump inhibitors              | 64 (68.8)           | 36 (56.2)               | 38 (50.0)               |
| NSAIDs                              | 11 (11.8)           | 3 (4.7)                 | 7 (9.2)                 |
| Immunosuppressive agents            | 54 (58.8)           | 38 (59.4)               | 34 (44.7)               |
| Cytostatic agents                   | 21 (22.6)           | 13 (20.3)               | 11 (14.5)               |
| Nasogastric tube                    | 39 (44.3)           | 29 (45.3)               | 20 (28.2)               |
| Abdominal surgery                   | 35 (37.6)           | 24 (37.5)               | 20 (28.6)               |
| Endoscopy                           | 28 (31.5)           | 16 (25.0)               | 10 (13.2)               |
| Previous admission                  | 68 (74.7)           | 19 (30.2)               | 30 (41.7)               |
| Previous admission to ICU           | 26 (28.0)           | 12 (18.8)               | 5 (6.6)                 |

- ◦ N between 88 and 93
- ◦◦ N between 62 and 64
- ◦◦◦ N between 71 and 76

ICU: intensive care unit
NSAIDs: non-steroidal anti-inflammatory drugs
Table 2: Crude and adjusted odds ratios for development of CDI and non-CDI diarrhea.

| Risk factors                  | CDI vs. Control | Non-CDI vs. Control |
|------------------------------|-----------------|---------------------|
|                              | Crude odds ratio (95% C.I.) | Adjusted odds ratio (95% C.I.) | Crude odds ratio (95% C.I.) | Adjusted odds ratio (95% C.I.) |
| Age > 65 years               | 1.77 (0.90-3.49)  | ^ 1.82 (0.92-3.62)  | ^ 1.26 (0.59-2.69)  | 1.17 (0.54-2.55)  |
| Male sex                     | 1.29 (0.70-2.39)  | 1.30 (0.70-2.43)    | 0.85 (0.44-1.67)    | 0.88 (0.45-1.72)   |
| Charlson co-morbidity index  |                 |                     |                     |                     |
| 0                            | Reference        | Reference           | Reference           | Reference           |
| 1-2                          | 1.61 (0.70-3.72)  | 1.78 (0.73-4.37)    | 1.29 (0.53-3.13)    | 1.35 (0.50-3.66)   |
| 3-4                          | 2.11 (0.85-5.24)  | 2.42 (0.87-6.73)    | ^ 1.32 (0.49-3.57)  | 1.32 (0.41-4.30)   |
| 5+                           | 2.52 (0.80-7.95)  | 2.57 (0.76-8.65)    | 2.49 (0.76-8.19)    | 3.10 (0.82-11.7)   |
| Any underlying disease       |                 |                     |                     |                     |
| Hematologic malignancy       | 1.27 (0.54-3.01)  | 2.33 (0.86-6.23)    | 1.68 (0.68-4.15)    | 2.19 (0.70-6.88)   |
| Urogenital tract diseases    | 1.78 (0.95-3.36)  | ^ 1.97 (0.97-4.02)   | 1.06 (0.52-2.16)    | 0.99 (0.42-2.34)   |
| Other diseases               | 1.58 (0.83-3.02)  | 1.47 (0.72-3.00)    | 1.47 (0.73-2.99)    | 1.41 (0.65-3.07)   |
| Any antibiotic               | 6.82 (2.62-17.8)  | ^ 5.41 (1.79-16.3)   | 1.41 (0.67-2.98)    | 0.99 (0.40-2.42)   |
| Proton pump inhibitors       | 2.21 (1.18-4.14)  | ^ 1.14 (0.51-2.58)   | 1.29 (0.66-2.51)    | 1.01 (0.46-2.22)   |
| NSAIDs                       | 1.32 (0.49-3.60)  | 0.86 (0.27-2.73)    | 0.49 (0.12-1.96)    | 0.34 (0.07-1.57)   |
| Immunosuppressive agents     | 1.71 (0.93-3.15)  | ^ 1.39 (0.64-3.06)   | 1.81 (0.92-3.54)    | 1.44 (0.64-2.32)   |
| Cytostatic agents            | 1.72 (0.77-3.85)  | 1.61 (0.61-4.24)    | 1.51 (0.62-3.64)    | 1.64 (0.58-6.63)   |
| Nasogastric tube             | 2.03 (1.04-3.95)  | ^ 1.50 (0.66-3.43)   | 2.11 (1.04-4.31)    | 1.77 (0.70-4.50)   |
| Abdominal surgery            | 1.51 (0.77-2.94)  | 1.17 (0.56-2.45)    | 1.50 (0.73-3.10)    | 1.28 (0.57-2.84)   |
| Endoscopy                    | 3.03 (1.36-6.75)  | ^ 2.64 (1.00-6.96)   | 2.20 (0.92-5.27)    | 2.63 (0.90-7.64)   |
| Previous admission           | 4.14 (2.13-8.05)  | ^ 4.49 (2.23-9.01)   | 0.61 (0.30-1.23)    | 0.55 (0.26-1.17)   |
| Previous admission to ICU    | 5.51 (2.00-15.2)  | ^ 5.47 (1.95-15.3)   | 3.28 (1.09-9.87)    | 2.64 (0.83-8.37)   |

^ Trend detected (p<0.10)
^^ Significant difference (p<0.05)

ICU: intensive care unit
NSAIDs: non-steroidal anti-inflammatory drugs
Table 3: The use of antibiotics expressed in Defined Daily Doses (DDDs) in patients with CDI and non-CDI diarrhea and control patients.

| Antibiotics   | CDI patients (N=93) | Non-CDI patients (N=64) | Control patients (N=76) | CDI vs. Control | Non-CDI vs. Control |
|---------------|---------------------|-------------------------|-------------------------|----------------|---------------------|
|               | N (%)               | N (%)                   | N (%)                   | Crude odds ratio (95% C.I.) | Adjusted odds ratio (95% C.I.) | Crude odds ratio (95% C.I.) | Adjusted odds ratio (95% C.I.) |
| Cephalosporins|                     |                         |                         |                 |                     |                     |                             |
| 1st generation| 13 (14.0)           | 5 (7.8)                 | 12 (16.0)               | 0.85 (0.36-2.00) | 0.79 (0.21-3.02)   | 0.45 (0.15-1.34) | 0.18 (0.04-0.84)          |
| 2nd generation| 46 (49.5)           | 20 (31.3)               | 14 (21.5)               | 4.26 (2.10-8.67) | 7.64 (2.42-24.2)  | 1.98 (0.90-4.34) | 0.97 (0.31-3.05)          |
| 3rd generation| 29 (31.2)           | 12 (18.8)               | 2 (3.1)                 | 16.5 (3.80-72.1) | 20.4 (3.50-119)   | 8.42 (1.81-39.2) | 9.53 (1.66-54.7)          |
| Penicillins   | 51 (54.8)           | 22 (34.4)               | 23 (30.7)               | 2.75 (1.45-5.20) | 1.47 (0.58-3.72)  | 1.18 (0.58-2.41) | 0.69 (0.27-1.74)          |
| Fluoroquinolones| 31 (33.3)         | 21 (32.8)               | 20 (26.7)               | 1.38 (0.70-2.69) | 0.57 (0.20-1.62)  | 1.34 (0.65-2.79) | 0.93 (0.32-2.70)          |
| Clindamycin   | 5 (5.4)             | 2 (3.1)                 | 1 (1.3)                 | 4.21 (0.48-36.8) | 0.75 (0.03-17.2)  | 2.39 (0.21-27.0) | 2.68 (0.14-50.2)          |
| Vancomycin    | 22 (23.7)           | 14 (21.9)               | 7 (9.3)                 | 3.01 (1.21-7.50) | 0.51 (0.11-2.40)  | 2.72 (1.02-7.23) | 1.55 (0.43-5.62)          |

* This information was known for all patients, except one control patient

^ Trend (p<0.10) detected

^^ Significant difference (p<0.05) detected
Figure 1: Survival curve of patients with CDI, non-CDI diarrhoea and control patients, in a period of 60 days after the reference date.